Episode # 178 • 16 Jul 2024
ASCO 2024: Game-Changing GU Oncology Updates in Bladder & Kidney Cancers
Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros Grivas from Fred Hutchinson Cancer Center and Dr. Sumanta (Monty) Pal from City of Hope.
This podcast is supported by
Timestamps
00:00 - Introduction
03:42 - Pembrolizumab and Enfortumab Vedotin Trial Insights
07:43 - Future Trials and Treatment Strategies
21:27 - Javelin Bladder 100 Trial Discussion
32:05 - Growth Factor Use
36:21 - Future Directions of Biomarkers
38:55 - Kidney Cancer Biomarker Trials
53:40 - Concluding Thoughts
You may also like
More about this episode
The conversation initially focuses on advanced urothelial carcinoma and the EV302 trial, discussing detailed insights from the quality-of-life results presented at ASCO. The experts offer relevant clinical perspectives for modern metastatic urothelial carcinoma management, focusing on pembrolizumab plus enfortumab vedotin. Further, they delve into breaking biomarker research at ASCO, including KIM-1 in adjuvant renal cell carcinoma (RCC) therapy and the HIF-2 inhibitor DFF332 for chromophobe RCC.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.